On the Immuno -oncology space an article here about an American company Janux developing novel solid tumor therapies,
it's therapies sound very similar to IMU CF33-CD 19 a mark and kill approach targeting proteins on tumor cells, but not CD19
it's shares tripled overnight when a licensing deal was announced company value jumped to $2B US. It was reported Investors liked the safety profile of it's drug over that of others in the same space.
My take is exactly what Lesley says data data data, safety, efficacy, = Rocketship
Interesting read for some enjoy
Janux shares triple on early cancer immunotherapy data | BioPharma Dive
Media Thread, page-14740
-
- There are more pages in this discussion • 372 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
-0.001(1.89%) |
Mkt cap ! $382.1M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.4¢ | 5.2¢ | $216.1K | 4.106M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 31 | 1854997 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.3¢ | 382882 | 4 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |